Compare F.N.B. Corporation Common Stock (FNB) vs Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Haleon plc American Depositary Shares (Each representing two Ordinary Shares) — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.88 (market cap $42.21B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 7× F.N.B. Corporation Common Stock's market cap, and F.N.B. Corporation Common Stock pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 3 Days on average.
| FNB | HLN | |
|---|---|---|
Market Cap | $6.03B | $42.21B |
Volume | 7,117,178 | 13,841,864 |
Sector | Financials | Health |
52-Week High | $19.49 | $11.27 |
52-Week Low | $14.65 | $8.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $10.52B | $52.02B |
Dividend Yield | 3.07% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.
The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →
